Vinblastine - Administration & dosage
Research News and Information

Monday, November 23, 2009

Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.

13 Dec 2009 Children with Down syndrome (DS) are at increased risk for the development of acute leukemia but they rarely develop other hematologic malignancies or solid tumors. Despite aggressive supportive care, DS patients have increased risk of treatment ... Read more...

Natural history and outcome of optic pathway gliomas in children.

13 Dec 2009 BACKGROUND: The optimal management of optic pathway gliomas (OPGs) is complicated by their variable natural history, the association with neurofibromatosis type 1 (NF1) and difficulties in defining progression and response to treatment. METHODS: ... Read more...

Preparation, characterization, in-vitro drug release and cellular uptake of poly(caprolactone) grafted dextran copolymeric nanoparticles loaded with anticancer drug.

13 Sep 2009 Biodegradable and biocompatible polymers that are engineered to nanostructures play a key role in providing solution for sustained chemotherapy. This study is focused on preparation, drug encapsulation efficiency, in-vitro drug release, in-vitro ... Read more...

Latest indexed articles for 'Vinblastine - Administration & dosage'

These are the very latest articles for this heading:

• Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma. 13 Dec 2009
• Natural history and outcome of optic pathway gliomas in children. 13 Dec 2009
• Preparation, characterization, in-vitro drug release and cellular uptake of poly(caprolactone) grafted dextran copolymeric nanoparticles loaded with anticancer drug. 13 Sep 2009
• Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC. 30 Aug 2009
• [A case of inflammatory carcinoma, well-controlled by chemotherapy, especially, vinorelbine, S-1 and trastuzumab] 30 Aug 2009
• Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. 29 Aug 2009
• Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. 23 Aug 2009
• Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. 22 Aug 2009
• Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. 15 Aug 2009
• Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. 8 Aug 2009
• Effect of corticosteroids on phlebitis induced by intravenous infusion of antineoplastic agents in rabbits. 4 Aug 2009
• International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. 3 Aug 2009
• Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. 12 Jul 2009
• All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. 5 Jul 2009
• [Plasmacytoid urothelial carcinoma of the bladder: a case report] 29 Jun 2009
• Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. 29 Jun 2009
• Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. 29 Jun 2009
• [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients] 30 May 2009
• A pure nongestational ovarian choriocarcinoma in a 10-year-old girl: case report and literature review. 30 May 2009
• A landmark point analysis with cytotoxic agents for advanced NSCLC. 30 May 2009

See a longer list of these articles.

Technical information about 'Vinblastine'

Definition: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Registry Number: 865-21-4

Descriptor UI: D014747

Alternative terms: Vinblastine; Vincaleukoblastine; Gastrozepin Brand of Vinblastine Sulfate; Faulding Brand of Vinblastine Sulfate; Vinblastinsulfat-Gry; Gry Brand of Vinblastine Sulfate; Velban; Vinblastina Lilly; Velbe; EG Labo Brand of Vinblastine Sulfate; Lilly Brand of Vinblastine Sulfate; Vinblastin Hexal; Hexal Brand of Vinblastine Sulfate; Vinblastine Sulfate; Sulfate, Vinblastine; cellblastin; cell pharm Brand of Vinblastine Sulfate; Lemblastine; Lemery Brand of Vinblastine Sulfate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; biosynthesis;

Pharmacological Action: Antineoplastic Agents, Phytogenic; Tubulin Modulators;

Tree Number: D03.132.436.681.827.650; D03.438.473.402.681.827.650;

Technical Notes: /biosyn permitted if by plant